Latest Quest Diagnostics Stories
AUSTIN, Texas, March 17, 2015 /PRNewswire/ -- Vermillion, Inc.
Proprietary Neurome(TM) service provides insight into the genetic causes of neurological disorders so parents and health care providers can develop personalized care strategies MADISON,
MADISON, N.J., Feb.
Agreement ensures continuing broad patient access to Quest's BRCAvantage(TM) services for evaluating genetic risk of developing breast, ovarian and other cancers MADISON, N.J., Feb.
Multi-year fee-based contract for Quest's test data and analytics expertise aims to reveal insights from national testing trends to promote guideline-based care and better outcomes for 4.4 million
MADISON, N.J., Jan.
CYPRESS, Calif. and MADISON, N.J., Dec.
MADISON, N.J., Dec.
First major service extension to the company's BRCAvantage(TM) BRCA1 and BRCA2 mutation test menu offers screening for five new non-BRCA genes shown to increase risk of inherited breast cancer MADISON,
MADISON, N.J., Oct.
- Large; stout; burly.